Abstract |
Recent guidelines in British Columbia, Canada have suggested that the use of a maximum of 3 monthly doses of palivizumab 15 mg/kg intramuscularly for RSV immunoprophylaxis of high risk infants born prior to the RSV season is adequate to provide protection against severe RSV disease for a 5-month RSV season. Efficacy was established, however, with 2 large, randomized controlled clinical studies using 5 monthly doses of immunoprophylaxis. To evaluate the differences in expected palivizumab exposures between the 2 dosing regimens (3 vs 5 monthly doses across a 5-month period), we used a population pharmacokinetic (PK) model that was developed using palivizumab PK data collected from 22 clinical studies with a total of 1800 subjects. This model adequately described observed palivizumab concentrations from the different pediatric studies and was subsequently used to simulate expected palivizumab serum concentrations for 3 monthly doses compared with 5 monthly doses in children younger than 24 months with chronic lung disease of prematurity and infants younger than 6 months postnatal age who were born at ≤ 35 weeks gestational age. Results from the population PK model indicated lower serum concentrations of palivizumab during the fourth and fifth months, after an abbreviated 3-monthly-dose regimen when compared with the mean trough concentrations seen with the 5-monthly-dose regimen studied in the pivotal clinical trials in premature infants. Specifically, during the fourth and fifth months, 52% and 85%, respectively, would have levels below the lowest concentration (fifth percentile) in those receiving the 5-monthly-dose regimen. Simulations using this model did not support a 3-monthly-dose regimen to protect against severe RSV disease during the typical 5-month season.
|
Authors | William V La Via, Gerard F Notario, Xiang-Qing Yu, Shringi Sharma, Peter A Noertersheuser, Gabriel J Robbie |
Journal | Pulmonary pharmacology & therapeutics
(Pulm Pharmacol Ther)
Vol. 26
Issue 6
Pg. 666-71
(Dec 2013)
ISSN: 1522-9629 [Electronic] England |
PMID | 23523663
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antiviral Agents
- Palivizumab
|
Topics |
- Age Factors
- Antibodies, Monoclonal, Humanized
(administration & dosage, pharmacokinetics)
- Antiviral Agents
(administration & dosage, pharmacokinetics)
- British Columbia
- Clinical Trials as Topic
- Drug Administration Schedule
- Humans
- Infant
- Injections, Intramuscular
- Models, Biological
- Palivizumab
- Practice Guidelines as Topic
- Respiratory Syncytial Virus Infections
(prevention & control)
- Risk Factors
- Time Factors
|